Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion **(Co-CTO)** trial  
*Supplemental material*

Yvemarie B.O. Somsen, MDa; Ruben W. de Winter, MDa; Jiawei Wu, MDb; Roel Hoek, MDa; Ralf W. Sprengers, MD, PhDc; Niels J. Verouden, MD, PhDa; Bimmer E.P.M. Claessen, MD, PhDd; Sebastiaan A. Kleijn, MD, PhDa; Jos W.R. Twisk, PhDe; José P. Henriques, MD, PhDd; James C. Spratt, MD, PhDf; Tuomas T. Rissanen, MD, PhDg; Margaret B. McEntegart, MD, PhDb; Akiko Maehara, MD, PhDb; Alexander Nap, MD, PhDa; Paul Knaapen, MD, PhDa.

Department of aCardiology , cRadiology & Nuclear Medicine and eEpidemiology & Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Department of bCardiology, New York-Presbyterian Hospital and Columbia University Medical Center, New York, United States of America.

Department of dCardiology Amsterdam UMC, AMC, Amsterdam, the Netherlands.

Department of fCardiology, St. George’s University Hospital, London, United Kingdom.

Department of gCardiology, North Karelia Central Hospital, Joensuu, Finland.

**Conflict of interest:** Nothing to Disclose | **Sources of funding:** P. Knaapen has received research grants from Boston Scientific Inc., Cleerly Inc., and Heartflow Inc. B.E. Claessen has received speaker or consultancy fees from Abiomed, Abbott Vascular, Bbraun, Amgen, Sanofi, Boston Scientific and Philips, and research funding grants from Sanofi, Philips, Novo Nordisk, Bbraun and Nipro/Infraredx.

**Brief title:** Co-CTO trial design

**Corresponding author:**

Paul Knaapen, MD, PhD - Professor of Cardiac Intervention & Imaging

Department of Cardiology Heart Center, Amsterdam UMC, location Vrije Universiteit Amsterdam

De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Email: p.knaapen@amsterdamumc.nl |Telephone: +31 (0)20 444 0123 | Fax: +31 (0)20 444 2446

**Supplemental material**

# CCTA scanner characteristics and scanning protocol

CCTA imaging is acquired with a 192-slice dual-source CT (DSCT) system (Somatom Force, Siemens Medical Solutions, Forchheim, Germany) with a collimation of 2 × 192 × 0.6 mm, using a flying focal spot technique and a gantry rotation time of 250 ms. A high-pitch spiral acquisition protocol will be used with a fixed pitch of 3.2, corresponding to a table movement of 7.37 m/s. Automatic tube voltage modulation and exposure control for tube current will be used, depending on patient characteristics. Images will be reconstructed using an iterative reconstruction technique (ADMIRE; Siemens Medical Solutions, Forchheim, Germany). The reconstruction parameters are: slice thickness 0.6 mm, increment 0.5 mm and Bv40 kernel. All CCTA high-pitch acquisitions will be performed with prospective ECG-triggering, with variable padding dependent on HR. For visualization of the coronary artery lumen a variably diluted bolus of 100 ml iobitidol (Xenetix 350) will be injected intravenously (5 mL/s), dependent on chosen tube voltage, followed immediately by a 50 mL saline chaser. The scan is triggered using an automatic bolus tracking technique, with a region of interest (ROI) placed in the descending thoracic aorta and a threshold of 100 HU. Metoprolol 100 mg will be administered orally for patients with a pre-scan HR > 65 bpm one hour before start of the CT protocol. If necessary, 5 to 20 mg metoprolol will be given intravenously during the scan to achieve a heart rate < 65 bpm. Each patient receives 400 to 800 mcg of sublingual nitroglycerine immediately before CCTA. The analysis of all CCTA imaging will be performed offline with commercially available software and by an independent dedicated corelab. Relevant parameters include (but are not limited to): %DS, in-segment binary restenosis, target vessel re-occlusion, volumetric plaque measurements, calcified and non-calcified plaque morphology, low attenuation plaque, and absent or spotty calcification.